TXMD (TherapeuticsMD) Total Stockholders Equity : $27.09 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Total Stockholders Equity?

TherapeuticsMD's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $27.09 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. TherapeuticsMD's Book Value per Share for the quarter that ended in Sep. 2024 was $2.35. The ratio of a company's debt over equity can be used to measure how leveraged this company is. TherapeuticsMD's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.27.

TherapeuticsMD Total Stockholders Equity Historical Data

The historical data trend for TherapeuticsMD's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Total Stockholders Equity Chart

TherapeuticsMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

9.20

-124.00

-93.62

35.14

29.29

TherapeuticsMD Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															28.05	29.29	28.66	27.67	27.09

TherapeuticsMD (NAS:TXMD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

TherapeuticsMD's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(27.094	-	0)	/	11.532
	=	2.35

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

TherapeuticsMD's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.623	+	5.777)	/	27.094
	=	0.27

TherapeuticsMD Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TherapeuticsMD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Executives

Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354
Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro	director
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017